VANCOUVER, Aug. 2 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced its financial results for the second quarter ended June
30, 2007. "We continued to focus on the development and
commercialization of our key catalyst products during the second
quarter," said Dr. William Hunter, President and CEO of Angiotech.
"In particular, we made significant strides in building out our
sales and marketing infrastructure, while at the same time reaching
important milestones such as securing a CE Mark for our Quill(R)
SRS product line." "Over the last quarter, we made good progress
with the continued implementation of our various growth,
organizational change, and operational improvement initiatives,
while at the same time delivering solid operating results,"
commented Thomas Bailey, Chief Financial Officer of Angiotech.
Financial Highlights - Total revenue, as adjusted for non-recurring
items, was $75.3 million in the second quarter. Total revenue under
generally accepted accounting principles ("GAAP") was $72.4
million. - Net product sales, as adjusted, of $45.4 million
increased $2.9 million, or 6.9%, as compared to the first quarter,
and were derived principally from sales of our various single use,
specialty medical devices, as well as from sales of medical device
components to third parties. - Royalty revenue was $29.9 million.
This includes $28.4 million of royalty revenue derived from sales
by Boston Scientific Corporation ("BSC") of paclitaxel-eluting
coronary stent systems. This represents an average gross royalty
rate of 7.6 percent for U.S. sales and 5.5 percent for sales in
other countries. - Adjusted EBITDA (earnings before interest,
taxes, depreciation and amortization, adjusted to exclude certain
non-cash, non-recurring, and other items) was $15.6 million. - GAAP
net loss from continuing operations and net loss per share from
continuing operations were $15.0 million and $0.18 respectively.
Our GAAP results reflect several non-recurring items, including:
in-process research and development expense of $8.0 million (the
majority of which related to the extension of our research
collaboration with CombinatoRx, Incorporated ("CombinatoRx"));
costs accrued of $3.0 million relating to the discontinuation of
our Contour Threads brand name; and restructuring costs of $2.1
million, the majority of which related to the closure of our
manufacturing facility in Syracuse, New York. - Adjusted net income
from continuing operations and adjusted net income per share from
continuing operations were $5.0 million and $0.06, respectively. -
An income tax recovery of $10.5 million as reported in our GAAP
results was derived from several concurrent factors, including
deductions related to the amortization of identifiable intangible
assets, deductions relating to certain international financing
structures, and provincial income tax credits. - Cash and long-term
investments were $144.2 million, and net debt was $437.2 million.
Business Highlights Our focus for 2007 continues to be on our three
main catalysts: Quill(R) SRS, 5-FU CVC and Vascular Wrap(TM). From
an operational perspective, we are building out our global sales
and marketing organization as well as organizing our business
operations for maximum capacity utilization, efficiency in the
supply chain, and ensuring that we have adequate manufacturing
capacity in the areas of anticipated growth in future years. We
made significant advancements on all of these fronts during the
second quarter. Quill(R) SRS - We secured European approval for CE
mark of our Quill(R) Self-Retaining System (SRS) and expect to
launch Quill(R) SRS commercially in Europe mid-year. Vascular
Wrap(TM) - We re-obtained the exclusive rights from Edwards
Lifesciences Corporation to market and distribute our Vascular
Wrap(TM)/ePTFE graft combination product candidate through our own
sales force and distribution network in Europe. - We initiated a
pivotal human clinical trial in Europe designed to evaluate the
safety and efficacy of the Vascular Wrap(TM) in the prevention of
stenosis following surgical implantation of an ePTFE vascular graft
in the upper extremity for vascular (AV) access in hemodialysis
patients. It is expected that results from this study will serve as
a base of European experience for CE Mark submission along with
supporting data from a similar U.S. pivotal trial initiated in
March. 5-FU CVC - Shortly after the end of the second quarter, we
completed enrolment of our 5-FU CVC pivotal study. We expect to
have preliminary data results compiled in the fall, and present the
final data in early 2008. Sales and Marketing - Expansion of the
sales and marketing team is on track in Europe, Asia, and the
United States, with key personnel hired into the Surgical,
Interventional and Specialties-OEM areas. Operations - As part of
our continuing effort to increase capacity utilization, reduce
labour and other direct manufacturing costs and ensure adequate
capacity in key growth areas, including Quill(R), we made the
decision to close our manufacturing facility in Syracuse, New York
and to transfer the product manufacturing and technical knowledge
to our operations in Puerto Rico and Reading, Pennsylvania. The
closure of the Syracuse facility will occur over the next twelve to
eighteen months. Other Business Highlights - Shortly after the end
of the second quarter, Cook Incorporated ("Cook") and BSC announced
several new human clinical trials of next-generation products
incorporating our proprietary paclitaxel technology. These trials
are of Cook's Zilver(R) PTX(TM) paclitaxel-eluting peripheral stent
for use in arteries outside of the heart, and of BSC's TAXUS
Petal(TM) bifurcation coronary stent and TAXUS Element(TM) platinum
chromium coronary stent respectively. - We announced the extension
of our collaboration agreement with CombinatoRx from the initial
two and a half year term to a total of five years. The
collaboration will continue to focus on evaluating and identifying
drug candidates that are combinations of known pharmaceutical
compounds that could be useful to treat selected local diseases or
in selected surgical or medical device applications. Financial
Information and Certain Non GAAP Financial Measures
------------------------------------------------------------- This
press release contains the condensed financial statements derived
from the unaudited consolidated interim financial statements for
the three- and six-month periods ended June 30, 2007, and audited
consolidated financial statements for the year ended December 31,
2006. Full unaudited consolidated interim financial statements and
Management's Discussion and Analysis for the three- and six-month
periods ended June 30, 2007, will be filed with the relevant
regulatory agencies, as well as posted on our website at
http://www.angiotech.com/. We completed the acquisition of the
operations of American Medical Instruments Holdings, Inc. ("AMI")
on March 23, 2006. Because of the timing of the AMI acquisition,
our operating results for the three month period ended June 30,
2006 include AMI's results of operations from the period of March
24, 2006 to June 30, 2006, as compared to the current quarter which
reflects combined results from the period of April 1, 2007 to June
30, 2007. Our results for the quarter ended June 30, 2007 therefore
reflect a slightly shorter time period, and as a result do not
reflect a comparable operating period as compared to the second
quarter of 2006. The results for the six month period ended June
30, 2007 fully include the results of AMI. As AMI was acquired on
March 23, 2006, the comparative six month period ended June 30,
2006 only includes the results of the AMI operations for the period
March 23, 2006 to June 30, 2007. Amounts, unless specified
otherwise, are expressed in U.S. dollars. Financial results are
reported under GAAP unless otherwise noted. All per share amounts
are stated on a diluted basis unless otherwise noted. Certain
financial results presented in this press release include non-GAAP
measures that exclude certain items. Adjusted net income from
continuing operations, adjusted net income per share from
continuing operations and adjusted earnings before interest, taxes,
depreciation and amortization ("adjusted EBITDA") exclude
acquisition related amortization charges, acquired in-process
research and development relating to license agreements and
acquisitions, stock-based compensation expense, foreign exchange
gains or losses relating to translation of foreign currency cash
and investment balances and other non-recurring items. Adjusted net
income from continuing operations, adjusted net income per share
from continuing operations and adjusted EBITDA also exclude
litigation expenses related to defending intellectual property
claims. Revenue, as adjusted, excludes non-recurring, non-operating
revenue derived from license agreements and other license revenue,
net of license fees due to licensors and excludes amounts accrued
for costs incurred, and potential future costs, related to our
offer to accept returns of Contour Threads brand product as part of
the brand name consolidation and discontinuation. Adjusted net
income from continuing operations, adjusted net income per share
from continuing operations, revenue from continuing operations, as
adjusted and adjusted EBITDA do not have any standardized meaning
prescribed by GAAP and therefore may not be comparable to similar
measures presented by other issuers. Management uses these non-GAAP
or adjusted operating measures to establish operational goals, and
believes that these measures may assist investors in analyzing the
underlying trends in our business over time. Investors should
consider these non-GAAP measures in addition to, not as a
substitute for, or as superior to, financial reporting measures
prepared in accordance with GAAP. We have provided a reconciliation
of these measures to GAAP in the attached tables. Conference Call
Information --------------------------- A conference call to
discuss these financial results will be held today, Thursday,
August 2, 2007 at 8:00 AM PT (11:00 AM ET). Dial-in information:
North America (toll free): (866) 578-5788 International: (617)
213-8057 Enter passcode: 78719252 A replay archive of the
conference call will be available until August 9, 2007 by calling
(888) 286-8010 (in North America) or (617) 801-6888 (International)
and entering Access Code 92205136. A live webcast will be available
to all interested parties through the Investors section of
Angiotech's website: http://www.angiotech.com/. Forward Looking
Statements -------------------------- Statements contained in this
press release that are not based on historical fact, including
without limitation statements containing the words "believes,"
"may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute
"forward-looking information" within the meaning of applicable
Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to,
comments with respect to our strategies or future actions, our
targets, expectations for our financial condition and the results
of, or outlook for, our operations, research development and
product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are
taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or
our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or
the failure to comply with, governmental regulations; adverse
results or unexpected delays in drug discovery and clinical
development processes; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development and to expand commercialization activities
or consummate acquisitions; sales numbers and future guidance
publicly provided by Boston Scientific Corporation regarding sales
of their paclitaxel-eluting coronary stent products; and any other
factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual
results expressed or implied by the forward-looking statements in
this report to differ materially from our actual results. These
operating risks include: our ability to attract and retain
qualified personnel; our ability to successfully complete
preclinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the ability of Boston
Scientific Corporation to successfully manufacture, market and sell
their paclitaxel-eluting coronary stent products; the continued
availability of capital to finance our activities; our ability to
continue to integrate into our business the operations of American
Medical Instruments Holdings, Inc. ("AMI"); our ability to achieve
the operational and other synergies and the other commercial or
financial benefits expected as a result of the acquisition of AMI;
and any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.
About Angiotech Pharmaceuticals Angiotech Pharmaceuticals, Inc. is
a global specialty pharmaceutical and medical device company with
over 1,500 dedicated employees. Angiotech discovers, develops and
markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSXNASDAQ:ANP) please visit our website at
http://www.angiotech.com/. Vascular Wrap(TM) is a trademark of
Angiotech Pharmaceuticals, Inc. Quill(R) and Contour Threads(R) are
registered trademarks of Quill Medical, Inc., a wholly-owned
subsidiary of Angiotech Pharmaceuticals, Inc. TAXUS Petal(TM) and
TAXUS Element(TM) are trademarks of Boston Scientific Corporation.
Zilver(R) PTX(TM) are trademarks of Cook Incorporated. ANGIOTECH
PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS (Unaudited) (in thousands of U.S.$, except share Three
months ended Three months ended and per share data) June 30, 2007
June 30, 2006
-------------------------------------------------------------------------
Adjust- Adjust- Reported ments Adjusted Reported ments Adjusted
REVENUE Royalty revenue 29,878 29,878 42,980 42,980 Product sales,
net 42,421 2,980 a 45,401 50,553 50,553 License fees 53 (53)b - 73
(73)b -
-------------------------------------------------------------------------
72,352 2,927 75,279 93,606 (73) 93,533
-------------------------------------------------------------------------
EXPENSES License and royalty fees 4,268 4,268 6,050 6,050 Cost of
products sold 25,085 (927)c 24,158 24,033 24,033 Research and
development 13,458 (781)d 12,677 11,833 (773)d 11,060 Selling,
general and administrative 24,363 (4,774)e 19,589 23,178 (3,809)e
19,369 Depreciation and amortization 8,328 (7,459)f 869 10,389
(9,613)f 776 In-process research and development 8,000 (8,000)g - -
-
-------------------------------------------------------------------------
83,502 (21,941) 61,561 75,483 (14,195) 61,288
-------------------------------------------------------------------------
Operating (loss) income (11,150) 24,868 13,718 18,123 14,122 32,245
-------------------------------------------------------------------------
Other (expense) income: Foreign exchange (loss) gain (505) 505 h -
2,135 (2,135)h - Investment and other (expense) income (994) 1,933
i 939 1,813 (685)j 1,128 Loss on sale/write- down of investments -
- - 1,064 (1,064)k - Interest expense on long-term debt (12,896)
568 l (12,328)(11,297) (314)l (11,611)
-------------------------------------------------------------------------
Total other (expense) income (14,395) 3,006 (11,389) (6,285)
(4,198) (10,483)
-------------------------------------------------------------------------
Income (loss) from continuing operations before income taxes
(25,545) 27,874 2,329 11,838 9,924 21,762 Income tax (recovery)
expense (10,500) 7,857 m (2,643) 9,669 (3,168)m 6,501
-------------------------------------------------------------------------
Income (loss) from continuing operations (15,045) 20,017 4,972
2,169 13,092 15,261
-------------------------------------------------------------------------
Net loss from discontinued operations, net of income taxes (170)
170 - (342) 342 -
-------------------------------------------------------------------------
Net (loss) income for the period (15,215) 20,187 4,972 1,827 13,434
15,261
-------------------------------------------------------------------------
Basic net (loss) income per common share from continuing operations
(0.18) 0.06 0.03 0.18 Diluted net (loss) income per common share
from continuing operations (0.18) 0.06 0.03 0.18
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average shares outstanding (000's) - basic 85,014 85,014
84,651 84,651 Weighted average shares outstanding (000's) - diluted
85,460 85,460 85,710 85,710
-------------------------------------------------------------------------
-------------------------------------------------------------------------
a. Amounts accrued for costs incurred, and potential future costs,
related to our offer to accept returns of Contour Threads brand
product as part of the brand name consolidation and
discontinuation. b. Non-recurring, non-operating revenue as derived
from other license revenue, net of license fees due to licensors.
c. Change in estimate of accounting for excess and obsolete
inventory resulting from the alignment during the second quarter of
2007 of inventory policies across our various manufacturing
operations. d. Research and development adjustments:
---------------------------------------------------------------------
Three months Three months ended June 30, ended June 30, 2007 2006
------------------------------- Stock-based compensation (531)
(773) Termination and reorganization costs related to the
integration of AMI (250) -
---------------------------------------------------------------------
(781) (773)
---------------------------------------------------------------------
e. Selling, general and administrative adjustments:
---------------------------------------------------------------------
Three months Three months ended June 30, ended June 30, 2007 2006
------------------------------- Stock-based compensation (774)
(1,007) Termination and reorganization costs related to the
integration of AMI (1,846) - Litigation expenses relating to
defending intellectual property claims (2,154) (2,802)
---------------------------------------------------------------------
(4,774) (3,809)
---------------------------------------------------------------------
f. Amortization of acquisition related intangible assets and
medical technologies. g. Non-recurring in-process research and
development expense relating to payments to CombinatoRx and Rex
Medical Inc. h. Foreign exchange fluctuations on foreign currency
net monetary assets. i. Write off of uncollectible tax receivable
and write off of certain capitalized costs. j. Gain on sale of Palo
Alto building - assets held for sale. k. Gain on redemption of
long-term, available-for-sale securities. l. Amortization of
deferred financing costs in 2007, and interest expense in 2006
related to the AMI transaction that was incurred in the first
quarter prior to the consolidation of the results of the AMI
operations acquired, which occurred in the second quarter of 2006.
m. Tax effects of adjustments a. through l. for the period.
Comparative for 2006 also includes non-recurring Quebec retroactive
tax adjustment of $8.7 million. ANGIOTECH PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (in
thousands of U.S.$, except share Six months ended Six months ended
and per share data) June 30, 2007 June 30, 2006
-------------------------------------------------------------------------
Adjust- Adjust- Reported ments Adjusted Reported ments Adjusted
REVENUE Royalty revenue 62,878 62,878 84,070 84,070 Product sales,
net 84,907 2,980 a 87,887 51,355 51,355 License fees 525 (525)b -
126 (126)b -
-------------------------------------------------------------------------
148,310 2,455 150,765 135,551 (126) 135,425
-------------------------------------------------------------------------
EXPENSES License and royalty fees 9,709 9,709 12,563 12,563 Cost of
products sold 47,877 (1,727)c 46,150 24,667 24,667 Research and
development 27,221 (3,890)d 23,331 21,488 (1,394)d 20,094 Selling,
general and administrative 47,818 (10,021)e 37,797 33,552 (8,216)e
25,336 Depreciation and amortization 16,483 (14,734)f 1,749 12,555
(11,176)f 1,379 In-process research and development 8,000 (8,000)g
- 1,042 (1,042)h -
-------------------------------------------------------------------------
157,108 (38,372) 118,736 105,867 (21,828) 84,039
-------------------------------------------------------------------------
Operating (loss) income (8,798) 40,827 32,029 29,684 21,702 51,386
-------------------------------------------------------------------------
Other (expense) income: Foreign exchange (loss) gain (403) 403 i -
2,306 (2,306)i - Investment and other income 7,808 (5,577)j 2,231
4,517 (685)k 3,832 Loss on sale/write- down of investments (8,157)
8,157 l - (413) 413 m - Interest expense on long-term debt (25,695)
1,126 n (24,569)(12,286) 675 n (11,611)
-------------------------------------------------------------------------
Total other (expense) income (26,447) 4,109 (22,338) (5,876)
(1,903) (7,779)
-------------------------------------------------------------------------
Income (loss) from continuing operations before income taxes and
cumulative effect of change in accounting policy (35,245) 44,936
9,691 23,808 19,799 43,607 Income tax (recovery) expense (14,940)
10,301 o (4,639) 14,058 (2,513)o 11,545
-------------------------------------------------------------------------
Income (loss) from continuing operations before cumulative effect
of change in accounting policy (20,305) 34,635 14,330 9,750 22,312
32,062
-------------------------------------------------------------------------
Net loss from discontinued operations, net of income taxes (5,791)
5,791 - (787) 787 -
-------------------------------------------------------------------------
Cumulative effect of change in accounting policy - - 399 (399) -
-------------------------------------------------------------------------
Net (loss) income for the period (26,096) 40,426 14,330 9,362
22,700 32,062
-------------------------------------------------------------------------
Basic net (loss) income per common share from continuing operations
(0.24) 0.17 0.12 0.38 Diluted net (loss) income per common share
from continuing operations (0.24) 0.17 0.12 0.37
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average shares outstanding (000's) - basic 85,008 85,008
84,593 84,593 Weighted average shares outstanding (000's) - diluted
85,488 85,488 85,777 85,777
-------------------------------------------------------------------------
-------------------------------------------------------------------------
a. Amounts accrued for costs incurred, and potential future costs,
related to our offer to accept returns of Contour Threads brand
product as part of the brand name consolidation and
discontinuation. b. Non-recurring, non-operating revenue as derived
from license agreements with Histogenics Corporation ($0.4 million
in 2007) and other license revenue, net of license fees due to
licensors. c. Change in estimate of accounting for excess and
obsolete inventory resulting from the alignment during the second
quarter of 2007 of inventory policies across our various
manufacturing operations, and non-recurring supply/distribution
agreement termination costs. d. Research and development
adjustments:
---------------------------------------------------------------------
Six months Six months ended June 30, ended June 30, 2007 2006
------------------------------- Stock-based compensation (973)
(1,394) License fees due to licensors related to non-recurring
license revenue (419) - Termination and reorganization costs
related to the integration of AMI (849) - Non-recurring
supply/distribution agreement termination costs (899) -
Non-recurring in-process research and development expense relating
to the signing of a technology and intellectual property license
agreement with an inventor (750)
---------------------------------------------------------------------
(3,890) (1,394)
---------------------------------------------------------------------
e. Selling, general and administrative adjustments:
---------------------------------------------------------------------
Six months Six months ended June 30, ended June 30, 2007 2006
------------------------------- Stock-based compensation (1,392)
(1,886) Termination and reorganization costs related to the
integration of AMI (3,385) - Litigation expenses relating to
defending intellectual property claims (4,994) (6,330)
Non-recurring supply/distribution agreement termination costs (250)
-
---------------------------------------------------------------------
(10,021) (8,216)
---------------------------------------------------------------------
f. Amortization of acquisition related intangible assets and
medical technologies. g. Non-recurring in-process research and
development expense relating to payments to CombinatoRx. and Rex
Medical Inc. h. Non-recurring in-process research and development
expense, relating primarily to $1.0 million payment due under
license agreement with Poly-Med, Inc i. Foreign exchange
fluctuations on foreign currency net monetary assets. j. Write off
of uncollectible tax receivable and write off of certain
capitalized costs, net of gain realized on recovery of investments.
k. Gain on sale of Palo Alto building - assets held for sale. l.
Net impact of loss and gain on redemption of investments of common
share holdings in Orthovita Inc. and NuVasive, Inc., respectively.
m. Loss on redemption of investments. n. Amortization of deferred
financing costs. o. Tax effects of adjustments a. through n. for
the period, including the reversal of tax reserves previously
booked. Comparative for 2006 also includes non-recurring Quebec
retroactive tax adjustment of $8.7 million. ANGIOTECH
PHARMACEUTICALS, INC. CALCULATION OF ADJUSTED EBITDA (Unaudited)
Three months ended Six months ended June 30, June 30, (in thousands
of U.S.$) 2007 2006 2007 2006
-------------------------------------------------------------------------
Net (loss) income on a GAAP basis (15,215) 1,827 (26,096) 9,362
Interest expense on long-term debt 12,896 11,297 25,695 12,286
Income tax (recovery) expense (10,649) 9,578 (18,830) 13,967
Depreciation and amortization 9,524 11,591 18,775 13,838
-------------------------------------------------------------------------
EBITDA (3,444) 34,293 (456) 49,453
-------------------------------------------------------------------------
Adjustments: Net loss from discontinued operations, excluding
depreciation, amortization and income tax expense included above
159 242 9,379 642 In-process research and development 8,000 - 8,000
1,042 Non-recurring research and development costs - - 750 -
Non-recurring revenue, net of license fees (53) (73) (106) (126)
Stock-based compensation 1,305 1,780 2,364 3,280 Litigation
expenses 2,154 2,802 4,994 6,330 Foreign exchange loss (gain) 505
(2,135) 403 (2,306) Investment and other income (939) (1,128)
(2,231) (3,832) Severance 1,846 - 3,984 - Supply/distribution
agreement termination costs 250 - 2,199 - E&O inventory
adjustment 927 927 - Contour Threads potential return costs accrual
2,980 - 2,980 - Write-off of capitalized costs 280 280 - Write-off
of uncollectible tax receivable 2,250 - 2,250 - Gain on sale of
Palo Alto building - (685) - (685) Gain realized on recovery of
investment - (1,064) (7,510) (1,064) Accrued interest income (597)
- (597) - Net loss on redemption of investments - - 8,157 1,477
Cumulative effect of change in accounting policy - - - (399)
-------------------------------------------------------------------------
Adjusted EBITDA 15,623 34,032 35,767 53,812
-------------------------------------------------------------------------
-------------------------------------------------------------------------
ANGIOTECH PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE
SHEETS (Unaudited) As at June December (in thousands of U.S.$) 30,
2007 31, 2006
-------------------------------------------------------------------------
ASSETS Cash and short-term investments 112,298 108,617 Accounts
receivable 25,408 25,231 Inventories 36,286 33,619 Deferred income
taxes 11,775 5,372 Other current assets 4,605 6,303 Assets from
discontinued operations, current portion 3,507 2,365
-------------------------------------------------------------------------
Total current assets 193,879 181,507
-------------------------------------------------------------------------
Long-term investments 31,869 53,840 Property and equipment, net
58,072 59,783 Intangible assets, net 235,938 244,955 Goodwill
641,943 630,770 Deferred income taxes 6,463 4,804 Deferred
financing costs 14,718 14,845 Other assets 704 255 Assets from
discontinued operations 4,961 15,116
-------------------------------------------------------------------------
Total assets 1,188,547 1,205,874
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities 85,403
67,950 Liabilities from discontinued operations 3,692 4,226
Long-term debt 575,000 575,000 Deferred income taxes 57,544 71,813
Other tax liabilities 5,538 - Other long-term liabilities 4,229
4,052 Stockholders' equity 457,141 482,833
-------------------------------------------------------------------------
Total liabilities and stockholders' equity 1,188,547 1,205,874
-------------------------------------------------------------------------
-------------------------------------------------------------------------
CONTACT: Analysts and Investors: Deirdre Neary, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 222-7056, ; Media: Jodi Regts, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 221-7930, DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Analysts and Investors: Deirdre Neary, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 222-7056, ; Media: Jodi Regts, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 221-7930,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024